SEARCH
GO

DOG OWNER INFORMATION
Dog Owners

Product Information

Key Points

  • Unlike any other treatment, Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved* disease-modifying osteoarthritis drug (DMOAD) in the veterinary market.
  • It slows the disease cycle of non-infectious arthritis in dogs and supports the cartilage matrix repair process, while diminishing joint damage.
  • Treats the underlying causes of canine arthritis, rather than just the symptoms.
  • Is proven to slow the disease cycle, support tissue repair, diminish joint and joint fluid damage.
  • Adequan® Canine is an intramuscular injection that reaches the joint within two hours. It delivers the dose more rapidly to the joints with an intramuscular injection than is possible with an oral medication.
  • After entering the cartilage, Adequan® Canine lasts for 72 hours.
  • Adequan® Canine contains a mixture of polysulfated GAGs (glycosaminaglycans) that helps it bind with connective tissue.
  • This intramuscular injection allows delivery of high levels of GAGs to synovial joints by avoiding the digestive enzymes of the GI tract.
  • Its relatively low molecular weight (3,000 to 15,000 daltons) allows PSGAG to move from the bloodstream through the synovial membrane and into the synovial fluid.
  • This intramuscular injection helps keep joints lubricated, making movement easier and increases comfort by indirectly reducing inflammation.
  • Adequan® Canine is a prescription-only product that can be dispensed and administered only by licensed veterinarians.

 
 

*NADA #141-038, Approved by FDA

Did You Know ...
Did You Know?

About 20% of all adult dogs in the U.S. suffer from canine arthritis.

Ethicon
Ethicon
Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Possible side effects (pain at injection site, diarrhea and abnormal bleeding) were mild, transient and self-limiting. Safety studies of PSGAG in breeding, pregnant or lactating dogs have not been conducted. Click here for full product information.


 
Interwoven VisualPreview: //nov-cont04.novartispharmaceutical.com/us/main/www.milbemite.novartis.us/WORKAREA/UserWorkArea/templatedata/components/opinion_lab.tpl







































Lockedopinion_lab.tpl
New Form Import Edit Upload Submit